Daiichi Sankyo is a Japanese drugmaker whose antibody-drug-conjugate Enhertu has become a global oncology blockbuster. It trades on the Tokyo Stock Exchange under code 4568, in the Pharmaceuticals sector.
Key Facts
| Item | Details |
|---|---|
| Ticker | 4568 |
| Exchange | Tokyo Stock Exchange (TYO: 4568) |
| Sector | Pharmaceuticals |
| Headquarters | Tokyo, Japan |
Bull Case & Risks
Bull Case
- Enhertu and ADC oncology leadership
- A deep antibody-drug-conjugate pipeline
- Major partnership economics (AstraZeneca/Merck)
Risks
- Concentration in key oncology assets
- Clinical and competitive risk
Outlook
Daiichi Sankyo has become a global oncology leader through Enhertu and its broader antibody-drug-conjugate platform.
Educational information only, not investment advice. Stocks carry risk including possible loss of principal; past performance does not guarantee future results.